CYP19A1 and breast cancer: Baseline differences between HBM cases and family controls reflect our study design given the biases inherent to those referred to NHS DXA services e.g. those receiving steroids, estrogen replacement, or aromatase inhibitors for breast cancer are more likely to be referred for DXA assessment.